Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 19 de 19
Filter
1.
Nederlands Tijdschrift voor Geneeskunde ; 166:22, 2022.
Article in Dutch | MEDLINE | ID: covidwho-2170132

ABSTRACT

OBJECTIVE: To describe the self-reported maternal adverse events (AEs) of covid-19 vaccination during pregnancy.

2.
Drug Safety ; 45(10):1190-1191, 2022.
Article in English | EMBASE | ID: covidwho-2085658

ABSTRACT

Introduction: In March 2021 first cases of thrombosis with thrombocytopenia syndrome (TTS), also called vaccine induced thrombosis with thrombocytopenia (VITT), were published and reported, raising a concern with the adenovector vaccine of AstraZeneca [1, 2]. One month later, TTS was also associated with the Janssen vaccine [3]. No conclusive evidence of VITT with mRNA vaccines is found [4]. In Europe, vaccination programmes were put on hold and the indications for use restricted. The role of pharmacovigilance was to monitor the events closely and estimate its frequency of occurrence. While mass vaccination campaigns were ongoing, information on case criteria and definitions was limited. In the Netherlands, internists wrote guidelines, organised centralised diagnostics for PF4 ELISA and HIPA tests and encouraged expert physicians to report suspected cases to The Netherlands Pharmacovigilance Centre Lareb [5]. Lareb managed to monitor TTS cases closely by a fast triage of relevant reports and strong collaboration with external specialists. Objective(s): Spontaneously reported cases of TTS in The Netherlands are described. Method(s): We used CDC classification criteria combined with Dutch guidelines to determine confirmed and strongly suspected cases. CDC classification recognizes 'tier 1' with thrombosis at unusual sites not requiring tests and 'tier 2' with common types of thrombosis and requiring confirmatory tests [6]. Result(s): In total, 75 cases of thrombocytopenia with any kind of thrombosis were reported. Only 26 reports met criteria of TTS, concerning 19 AstraZeneca, 5 Janssen and 2 mRNA vaccines. The majority (23;89%) of the cases was reported following the first dose. Reporting rates for AstraZeneca and Janssen were 7.7 and 5.7 per million vaccinations in total, respectively, and 13.4 per million vaccinations of the first dose with AstraZeneca. Patient and report characteristics are described in table 1. 'Tier 1' criteria were met in 15 cases. 'Tier 2' criteria were met in 6 cases and in 5 cases TTS was strongly suspected based on the Dutch guidelines. A functional HIPA test was performed in 20 cases of which 17 were positive and 3 negative. Also, two reports were received with mRNA vaccines, one well documented with positive PF4-ELISA and HIPA-tests (Moderna, 3rd dose) and the other poorly documented but meeting 'tier 1' criteria (Pfizer, 1st dose). Conclusion(s): In The Netherlands, TTS was predominantly reported after the first dose of the AstraZeneca vaccine, similar to other countries [1]. Intensive collaboration between clinical practice and pharmacovigilance resulted in good monitoring of TTS cases with spontaneous reporting.

3.
Drug Safety ; 45(10):1308-1309, 2022.
Article in English | EMBASE | ID: covidwho-2085657

ABSTRACT

Introduction: Spontaneous reporting (SR) is a key method for monitoring the safety of COVID-19 vaccines used in the pandemic in 2021. SR led to early warnings of vaccine-induced-thrombosis-withthrombocytopenia (VITT) with the vector vaccines of AstraZeneca and Janssen [1-3]. In addition, an increase of reports of other thromboembolic events with both vector and mRNA vaccines was seen. For now, venous thromboembolism (VTE) is labelled for Janssen and cerebral-venous-thrombosis (CVST) for the AstraZeneca vaccines [4,5]. Because a large population is vaccinated in a short period of time and the fact that venous (VTE) and arterial thrombosis (ATE) are quite common conditions, the number of reports should be compared with background incidence rates as part of signal detection. Objective(s): We evaluated the use of Standardised Morbidity Rates (SMR) to compare spontaneously reported cases of thromboembolism with COVID-19 vaccines with stratified Dutch background incidence rates from 2019 in the vaccine exposed population. Method(s): SMRs are calculated by dividing the reported as observed (O) cases by the expected (E) number within risk windows of 14/28 days following each dose and vaccine. SMR>1 indicates that more cases were reported than expected [6]. Result(s): Until 9 December 2021, 2080 reports were received concerning at least one thromboembolic event with 24 million administered COVID-19 vaccines. These concerned 1000 of VTE, 956 of ATE, 19 of CVST and 134 reports of miscellaneous forms of thrombosis. Cases of VITT (TTS) were excluded. In the table the main results are summarized and highlighted. For AstraZeneca, SMRs reach or exceed 1 for VTE, ATE and CVST, especially in people aged <60 years. With the second dose of mRNA vaccines more cases of the rare condition CVST were observed in men, although absolute numbers are low;n = 3 for men with 2nd dose of Pfizer (14 days) and n = 1 for men with 2nd dose of Moderna (28 days). Conclusion(s): SMRs can be used when the exposed population is defined, stratified background incidence rates are available and the reporting rate is substantial. The rate of underreporting is unknown, differs in population subgroups, and is influenced by media attention. Therefore, SMRs near 1 are also considered to be 'high'. Our data cannot confirm nor exclude a potential signal of other types of thromboembolism with COVID-19 vaccines. But the potential signal initiated further epidemiological research to confirm and quantify a potential increased risk of thromboembolism with COVID-19 vaccines. (Table Presented).

4.
Drug Safety ; 45(10):1188-1189, 2022.
Article in English | EMBASE | ID: covidwho-2085656

ABSTRACT

Introduction: Pericarditis and myocarditis have been recognized as rare adverse drug reactions of the mRNA COVID-19 vaccines of Pfizer and Moderna [1,2]. Most cases are observed in young males within 5 days following the 2nd dose and the course is often mild. The estimated excess risk is about 1-3 per 100,000 vaccinated persons, whereas the risk ratios following Sars-CoV-2 infection are 5-18 for myocarditis and pericarditis respectively [3]. Few studies indicate an increased risk of myocarditis with the 1st dose of the vector vaccine of AstraZeneca [4]. General incidence of myocarditis is 10-20 per 100,000 personyears and young men are at increased risk. Incidencerates of pericarditis are not exactly known, since the condition is often self-limiting and underdiagnosed [5]. Objective(s): We evaluated the use of Standardised Morbidity Rates (SMR) to compare spontaneously reported cases of myocarditis and pericarditis with COVID-19 vaccines with stratified Dutch background incidence rates from 2019 in the vaccine exposed population. Method(s): SMRs are calculated by dividing the reported as observed (O) cases by the expected (E) number within risk windows of 5/14 days following each dose and vaccine. SMR>1 indicates that more cases were reported than expected [6]. Result(s): Until January 2022, 373 reports of myocarditis and pericarditis were received. The majority of the cases was reported following an mRNA vaccination (85%), mostly following the second dose (47%). The mean age for men and women was 34.7-45.1 years for myocarditis and 45.2-46.6 years for pericarditis. The mean times to onset (TTO) for myocarditis and pericarditis with the 1st and 2nd doses are about three weeks, with a wide range. Median TTO show a latency of 5 days for myocarditis and 9-14 days for pericarditis. Six patients died following myocarditis or pericarditis. In the table, SMRs for myocarditis within 5 days are summarized, stratified for vaccine, dose, sex and age. For pericarditis, SMRs show a similar pattern, and more reports were received than expected in men and women<40 years with all doses of Pfizer, in men <40 with Moderna, in men <40 and women>40 with the first dose of AstraZeneca and in men who received the Janssen vaccine. Conclusion(s): Myocarditis and pericarditis were reported more frequently than expected in various patient groups with both mRNA and vector vaccines. However, spontaneous reporting is signal generating and epidemiological studies are needed to confirm the potential signal with vector vaccines.

5.
Pharmacoepidemiology and Drug Safety ; 31:623-623, 2022.
Article in English | Web of Science | ID: covidwho-2084248
6.
Drug Safety ; 45(10):1190-1191, 2022.
Article in English | ProQuest Central | ID: covidwho-2045393

ABSTRACT

Introduction: In March 2021 first cases of thrombosis with thrombocytopenia syndrome (TTS), also called vaccine induced thrombosis with thrombocytopenia (VITT), were published and reported, raising a concern with the adenovector vaccine of AstraZeneca [1, 2]. One month later, TTS was also associated with the Janssen vaccine [3]. No conclusive evidence of VITT with mRNA vaccines is found [4]. In Europe, vaccination programmes were put on hold and the indications for use restricted. The role of pharmacovigilance was to monitor the events closely and estimate its frequency of occurrence. While mass vaccination campaigns were ongoing, information on case criteria and definitions was limited. In the Netherlands, internists wrote guidelines, organised centralised diagnostics for PF4 ELISA and HIPA tests and encouraged expert physicians to report suspected cases to The Netherlands Pharmacovigilance Centre Lareb [5]. Lareb managed to monitor TTS cases closely by a fast triage of relevant reports and strong collaboration with external specialists. Objective: Spontaneously reported cases of TTS in The Netherlands are described. Methods: We used CDC classification criteria combined with Dutch guidelines to determine confirmed and strongly suspected cases. CDC classification recognizes 'tier 1' with thrombosis at unusual sites not requiring tests and 'tier 2' with common types of thrombosis and requiring confirmatory tests [6]. Results: In total, 75 cases of thrombocytopenia with any kind of thrombosis were reported. Only 26 reports met criteria of TTS, concerning 19 AstraZeneca, 5 Janssen and 2 mRNA vaccines. The majority (23;89%) of the cases was reported following the first dose. Reporting rates for AstraZeneca and Janssen were 7.7 and 5.7 per million vaccinations in total, respectively, and 13.4 per million vaccinations of the first dose with AstraZeneca. Patient and report characteristics are described in table 1. 'Tier 1' criteria were met in 15 cases. 'Tier 2' criteria were met in 6 cases and in 5 cases TTS was strongly suspected based on the Dutch guidelines. A functional HIPA test was performed in 20 cases of which 17 were positive and 3 negative. Also, two reports were received with mRNA vaccines, one well documented with positive PF4-ELISA and HIPA-tests (Moderna, 3rd dose) and the other poorly documented but meeting 'tier 1' criteria (Pfizer, 1st dose). Conclusion: In The Netherlands, TTS was predominantly reported after the first dose of the AstraZeneca vaccine, similar to other countries [1]. Intensive collaboration between clinical practice and pharmacovigilance resulted in good monitoring of TTS cases with spontaneous reporting.

7.
Drug Safety ; 45(10):1308-1309, 2022.
Article in English | ProQuest Central | ID: covidwho-2045392

ABSTRACT

Introduction: Spontaneous reporting (SR) is a key method for monitoring the safety of COVID-19 vaccines used in the pandemic in 2021. SR led to early warnings of vaccine-induced-thrombosis-withthrombocytopenia (VITT) with the vector vaccines of AstraZeneca and Janssen [1-3]. In addition, an increase of reports of other thromboembolic events with both vector and mRNA vaccines was seen. For now, venous thromboembolism (VTE) is labelled for Janssen and cerebral-venous-thrombosis (CVST) for the AstraZeneca vaccines [4,5]. Because a large population is vaccinated in a short period of time and the fact that venous (VTE) and arterial thrombosis (ATE) are quite common conditions, the number of reports should be compared with background incidence rates as part of signal detection. Objective: We evaluated the use of Standardised Morbidity Rates (SMR) to compare spontaneously reported cases of thromboembolism with COVID-19 vaccines with stratified Dutch background incidence rates from 2019 in the vaccine exposed population. Methods: SMRs are calculated by dividing the reported as observed (O) cases by the expected (E) number within risk windows of 14/28 days following each dose and vaccine. SMR >1 indicates that more cases were reported than expected [6]. Results: Until 9 December 2021, 2080 reports were received concerning at least one thromboembolic event with 24 million administered COVID-19 vaccines. These concerned 1000 of VTE, 956 of ATE, 19 of CVST and 134 reports of miscellaneous forms of thrombosis. Cases of VITT (TTS) were excluded. In the table the main results are summarized and highlighted. For AstraZeneca, SMRs reach or exceed 1 for VTE, ATE and CVST, especially in people aged < 60 years. With the second dose of mRNA vaccines more cases of the rare condition CVST were observed in men, although absolute numbers are low;n = 3 for men with 2nd dose of Pfizer (14 days) and n = 1 for men with 2nd dose of Moderna (28 days). Conclusion: SMRs can be used when the exposed population is defined, stratified background incidence rates are available and the reporting rate is substantial. The rate of underreporting is unknown, differs in population subgroups, and is influenced by media attention. Therefore, SMRs near 1 are also considered to be 'high'. Our data cannot confirm nor exclude a potential signal of other types of thromboembolism with COVID-19 vaccines. But the potential signal initiated further epidemiological research to confirm and quantify a potential increased risk of thromboembolism with COVID-19 vaccines.

8.
Drug Safety ; 45(10):1188-1189, 2022.
Article in English | ProQuest Central | ID: covidwho-2045391

ABSTRACT

Introduction: Pericarditis and myocarditis have been recognized as rare adverse drug reactions of the mRNA COVID-19 vaccines of Pfizer and Moderna [1,2]. Most cases are observed in young males within 5 days following the 2nd dose and the course is often mild. The estimated excess risk is about 1-3 per 100,000 vaccinated persons, whereas the risk ratios following Sars-CoV-2 infection are 5-18 for myocarditis and pericarditis respectively [3]. Few studies indicate an increased risk of myocarditis with the 1st dose of the vector vaccine of AstraZeneca [4]. General incidence of myocarditis is 10-20 per 100,000 personyears and young men are at increased risk. Incidencerates of pericarditis are not exactly known, since the condition is often self-limiting and underdiagnosed [5]. Objective: We evaluated the use of Standardised Morbidity Rates (SMR) to compare spontaneously reported cases of myocarditis and pericarditis with COVID-19 vaccines with stratified Dutch background incidence rates from 2019 in the vaccine exposed population. Methods: SMRs are calculated by dividing the reported as observed (O) cases by the expected (E) number within risk windows of 5/14 days following each dose and vaccine. SMR > 1 indicates that more cases were reported than expected [6]. Results: Until January 2022, 373 reports of myocarditis and pericarditis were received. The majority of the cases was reported following an mRNA vaccination (85%), mostly following the second dose (47%). The mean age for men and women was 34.7-45.1 years for myocarditis and 45.2-46.6 years for pericarditis. The mean times to onset (TTO) for myocarditis and pericarditis with the 1st and 2nd doses are about three weeks, with a wide range. Median TTO show a latency of 5 days for myocarditis and 9-14 days for pericarditis. Six patients died following myocarditis or pericarditis. In the table, SMRs for myocarditis within 5 days are summarized, stratified for vaccine, dose, sex and age. For pericarditis, SMRs show a similar pattern, and more reports were received than expected in men and women < 40 years with all doses of Pfizer, in men < 40 with Moderna, in men < 40 and women > 40 with the first dose of AstraZeneca and in men who received the Janssen vaccine. Conclusion: Myocarditis and pericarditis were reported more frequently than expected in various patient groups with both mRNA and vector vaccines. However, spontaneous reporting is signal generating and epidemiological studies are needed to confirm the potential signal with vector vaccines.

9.
Lung India ; 39(SUPPL 1):S139, 2022.
Article in English | EMBASE | ID: covidwho-1857839

ABSTRACT

As of December 2021, India has over 34.8 million cases of COVID 19, an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It has been a massive problem to society with variable manifestations in human, and there has been numerous reported cases of covid 19 patients presenting with broad spectrum of cardiovascular (CV) manifestations. This case presented 3 patients with CV complication of COVID 19 leading to vascular ischemia, cardiac tamponade and ST elevated myocardial infarction All patients presented with chief complaint of high grade fever and shortness of breath. The first patient was a healthy and young 24-year-old male having pain in the right thigh with swelling. Doppler ultrasound of limbs showed poor venous flow indicating vascular ischemia. 2nd patient was 60-year-old women with upper respiratory symptoms diagnosed with Covid 19 and had progressive dyspnoea. She was found to have a hemorrhagic pericardial effusion with echocardiographic signs of tamponade and grade 2 cardiomegaly. Third patient was a 59 years old diabetic male diagnosed with ST elevated myocardial infraction represented by elevated cardiac enzymes, raised troponin I, ST elevation in anterior and septal leads and akinesia in the region of left anterior descending coronary artery (LAD). Covid 19 infection has common respiratory foot prints identified by knowledge of clinical presentation however, it has also extra- pulmonary cardiac and Vascular Stigmas which can be of serious consequences.

10.
Chemical Senses ; 46, 2021.
Article in English | EMBASE | ID: covidwho-1665928

ABSTRACT

We identified associations between measured olfactory dysfunction (OD) and dietary parameters in a nationally representative sample of US adults. In NHANES 2013-2014, 3,206 adults 40 and over completed a measured smell exam (8-item odor identification test) as well as a 24-hour dietary recall interview administered by trained interviewers. OD was defined as incorrect identification of 3 or more (out of 8) odors;severe OD was defined as incorrect identification of 5 or more odors. Diet quality was assessed using the Healthy Eating Index 2015 (HEI-2015), where higher scores indicate higher diet quality. Other dietary variables included 24-h energy intake, and % energy from fat, added sugar, and alcohol. Survey-weighted multiple linear regression models estimated independent associations between OD and dietary variables. Models were stratified by sex, and adjusted for age, race/ethnicity, education, income, smoking and chronic disease status. The prevalence rates of OD and severe OD were 12.8% (95% CI: 10.8%, 15.2%) and 2.5% (95% CI: 1.9%, 3.5%), respectively;the average HEI-2015 score was 52.9 (0.7 SE). In men, severe OD was associated with lower energy intake with an adjusted mean difference of -403.9 (95% CI: -710.4, -97.3) between those with and without severe OD. In women, severe OD was associated with lower % of energy intake from alcohol with an adjusted mean difference of -1.71 (95% CI: -2.5, -0.95). No significant associations were observed with other dietary variables. These findings are generally consistent with the broader view that disrupted olfactory function often has meaningful dietary implications, a concern with increased public health relevance given the transient and persistent olfactory disruption observed with COVID-19 infections.

11.
Drug Safety ; 44(12):1418-1419, 2021.
Article in English | ProQuest Central | ID: covidwho-1543533

ABSTRACT

Background/Introduction: The rapid deployment of COVID-19 vaccines has put the safety of these vaccines in the spot light. So far four COVID-19 vaccines are approved in Europe: mRNA vaccines from Pfizer and Moderna and viral vector vaccines from AstraZeneca and Janssen. Common Adverse Events following Immunization (AEFI) for these vaccines include manifestation of the inflammatory response such as pain, redness, swelling and pyrexia. To provide more insight in differences in vaccinated population in terms of age, gender, and medical background in relation to reactogenicity, data from the Dutch COVID-19 vaccine Cohort Event Monitoring were used. Objective/Aim: To explore factors that are associated with the occurrence of COVID-19 vaccine reactogenicity after the first dose in the Netherlands. Methods: A web-based prospective cohort design using patient reported outcomes was used [1]. Dutch participant, vaccinated with a COVID-19 vaccine, and registered for this study during February to May 2021 were included. A baseline questionnaire gives information on participant characteristics (age, gender, length, weight), comorbidities, concomitant medication, use of an antipyretic drug several hours before or after vaccination, and a history of experienced COVID-19 disease demonstrated by a positive test. The questionnaire about AEFI was sent 7 days after vaccination. Multivariable logistic regression analysis was used for analysis, with significance level of < 0.05. Results: Out of 21.822 participants included, 11.542 (52.9%) experienced reactogenicity. Compared to the Pfizer vaccine, the highest odds ratio (OR) for developing reactogenicity was for the AstraZeneca vaccine (OR 4.18) followed by Moderna (OR 1.77), and Janssen (OR 1.74). Participants with a history of COVID-19 disease had a 2.3 increased odds for reactogenicity. Women had a 2.04 increased odds compared to men. Older participants experienced less reactogenicity. Compared to the age group < 50, the ORs for the age groups 50-60, 61-79, and > 80 were 0.51, 0.26, and 0.16 respectively. Comorbidities that were associated with reactogenicity were cardiac disorders (OR 1.15), musculoskeletal disorders (OR 1.34), respiratory disorders (OR 1.20), and infections (1.88). A body mass index of 25.0-29.9 and over 30 was negatively associated with reactogenicity (OR 0.90 and OR 0.71 respectively). Conclusion: This extensive study with over 21.000 participants demonstrated that, taken into account all factors in the model, the mRNA vaccine from Pfizer gave the least reactogenicity. A person with a history of COVID-19 disease, female sex, younger age, and those with cardiac, musculoskeletal, respiratory disorders or infections had an increased odds for experiencing reactogenicity.

12.
Drug Safety ; 44(12):1418, 2021.
Article in English | ProQuest Central | ID: covidwho-1543503

ABSTRACT

Background/Introduction: Early 2021, the COVID-19 vaccination campaign in the Netherlands started. The Netherlands Pharmacovigilance Centre Lareb had to deal with high volumes of ICSRs, to be processed and assessed in a short time span. This necessitated the development of a dedicated system to enable a near real-time vaccine monitoring. Objective/Aim: To describe the development of an infrastructure which allows processing and assessment of large volumes of ISCRs during the COVID-19 vaccination campaign in the Netherlands. Methods: A specific COVID vaccine web-based reporting form enabled collecting information on the vaccine administered, Adverse Events Following Immunisation (AEFIs) and other information needed for assessment and signal detection. Conditional questions were developed to collect high quality information on specific AEFIs. Preselected fields were mapped to corresponding ICH e2B(R3) fields in the ICSR management system. Where not known and with permission from the reporter, batch numbers were retrieved from the national vaccination registry (CIMS) maintained by RIVM. A fully automatic process for reports enabled handling of the majority of common and known reported AEFIs. All other ICSRs were triaged daily. We arranged a non-priority team that handled reports on most common AEFIs and reports we selected as non-priority;and a high-priority team, consisting of medical doctors and pharmacists with vaccine-expertise, for assessing more complex and also serious reports. The latter team was also responsible for signal detection. Results: Up to June 1st 2021, Lareb received 75.840 ICSRs. This is a reporting rate of approximately 1% of the total amounts of vaccines given in the Netherlands. Fully automatic processing was possible for 48.3% of all received ICSRs on daily basis, making these reports directly available for signal detection. After daily triage of all remaining incoming ICSRs, 4.7% is flagged as a high priority report. The other 47.0% of the non-priority reports could be handled within a few minutes by the assessor. Batch-numbers were added from CIMS in 79% of the retrieval in Q1. With this way of working, we managed processing all ICSRs for signal detection on a daily basis. 99,99% of the serious ICSRs was compliant with a 15 days timeframe for Eudravigilance. The nonserious reports were processed within five weeks (100% compliancy). Conclusion: A new approach which is highly technical supportive enabled to process about 5.000 reports every week. This process can also be used to handle other vaccine ISCRs in the future.

13.
Acta Medica Mediterranea ; 37(5):2593-2597, 2021.
Article in English | Scopus | ID: covidwho-1449392

ABSTRACT

Introduction: Immunocompromised patients, SARS-CoV-2 infection might have a more severe course and may cause pneumonia quicker, compared to normal hosts. The presence of comorbid diseases increases this risk even further. In our study, we aimed to determine the clinical course and severity of COVID-19 in immunocompromised patients. Materials and method: Our study was carried out between 01 April 2020 and 01 October 2020 in 4 centers as a retrospective case-control study. Firstly, COVID-19 positive patients with previous immunosuppressive disorder diagnosis or patients who use immunosuppressive medicines for any reason were enrolled in the case group. COVID-19 rtRT-PCR positive patients who have no previous immunosuppressive disorder diagnosis and who are not on any immunosuppressive medicines were enrolled in the control group. Definitive statistical analysis was conducted for all of the researched variables. Results: 156 immunocompromised patients with COVID-19 diagnosis were enrolled in the case group of patients and 312 non-immunocompromised patients with COVID-19 diagnosis were enrolled in the control groups. In immunocompromised patients, CMI scores, the prevalence of hypertension, respiratory rate/minute, shortness of breath, and weakness were high and complaints about fever were low. In these patients, CRP, D-dimer, ferritin, and troponin values were high at statistically significant levels and lymphocyte values were low. The need for intensive care for immunocompromised patients was 2.93 times more and nosocomial infections and thrombotic complications occurred more frequently. Mortality was 3.57 times higher in immunocompromised patients. Conclusion: SARS-CoV-2 has a more severe course in immunocompromised patients. However, when evaluating these patients, whether or not the underlying diseases are under control should be evaluated and thrombotic complications and nosocomial infections should be taken into account. © 2021 A. CARBONE Editore. All rights reserved.

14.
Acta Medica Mediterranea ; 37(5), 2021.
Article in English | Scopus | ID: covidwho-1449390

ABSTRACT

Background: In SARS-COV-2 disease, anosmia and dysgeusia are symptoms that are usually detected together. In our study, it was aimed to investigate the impairments in the sense of smell and taste in our COVID-19 patients and to determine the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of the parameters accompanying this impairment. Methods: The study was conducted retrospectively in patients with positive COVID-19 rtRT-PCR test, whose complaints of smell-taste dysfunction were questioned in 6 centers. Result: 8238 patients questioned for the impaired sense of smell and taste were included in our study. 1756 (21.3%) patients had smell-taste dysfunction. Smell dysfunction started 2.9±2.3 days after the onset of COVID-19 specific symptoms and continued for 9.4±2.7 days. There was a positive correlation between the disturbance of smell and taste and the complaints of fever, sore throat, myalgia, weakness, headache, and negative correlation the complaints of cough. 218 (12.4%) of the patients with smell-taste dysfunction stated that this complaint negatively affected their quality of life. Conclusion: Smell-taste dysfunction is more common, especially with the symptoms of upper respiratory tract infection of COVID-19, and has a positive correlation with fever, sore throat, myalgia, weakness, and headache, affects the quality of life of patients and improves in about 10-14 days. © 2021 A. CARBONE Editore. All rights reserved.

15.
European Journal of Molecular and Clinical Medicine ; 8(3):3346-3352, 2021.
Article in English | EMBASE | ID: covidwho-1268936

ABSTRACT

Introduction: The implementation of efforts to prevent the rapid community spread of Covid-19 slowed the spread of infection, however it also affected the routine antenatal care as well as emergency obstetric care. This study was planned to find out the number of obstetrical emergency admissions and their outcomes in the form of procedures done, maternal mortality and intrauterine dead fetus in our rural tertiary care center during Covid-19 pandemic and compare it before Covid-19 pandemic in India. Material and methods: This study was a retrospective observational study conducted over a period of 1 year (6 month during Covid-19 pandemic in India from April 2020 to September 2020 and 6 months before Covid 19 pandemic). All the patients who were admitted in the Covid-19 labour room as well as in the non Covid-19 labour room of our institute were included in the study. Ethical clearance for the study was taken from ethical committee of institute before study. Data was collected from hospital record and patients case sheets. Comparison of data before and during Covid-19 pandemic was done by using chi square test and p values analysed. Results: During the total study period of 12 months including 6 months during Covid-19 pandemic and 6 months before pandemic the total number of admissions in obstetrical emergency ward were 7630 out of which 5806 admissions (76.1%) were before Covid-19 pandemic and 1824 admissions were (23.9%) during Covid-19 pandemic and it showed significant reduction (p value <0.001) in emergency obstetrical admissions during pandemic. Out of total admissions, the number of cesareans were more during Covid-19 pandemic as compared to before it. Thus it showed significant increase in (p value < 0.001) number of caesarean deliveries during Covid-19 pandemic at our institute. Maternal mortalities were 0.89% (52 in 5754 admissions) of obstetrical emergency admissions before Covid-19 pandemic whereas it was significantly increased during Covid-19 pandemic to 2.63%. Total number of Intrauterine death and still births were 180 in 2652 vaginal deliveries (6.7%) before Covid-19 pandemic which was also increased significantly to 108 in 842 vaginal deliveries (12.8%) during 6 month of study period during Covid-19 pandemic. Conclusions: In this study we observed significant reduction in number of admissions in obstetrical emergency ward whereas significant increase in maternal mortality and intrauterine dead fetus and stillborn babies during Covid-19 pandemic. We should educate the women that delay in seeking health care can have more dangerous complications than Covid-19 infection if they will follow the Covid-19 prevention protocols. More multicentric studies should be done in India to know the effect of Covid- 19 pandemic on maternal health care services so that effect of Covid-19 pandemic can be minimized and maternal and child care can be resumed earliest as before.

16.
Pharmaceutisch Weekblad ; 156(1-2):12-15, 2021.
Article in Dutch | EMBASE | ID: covidwho-1107032
17.
Pharmaceutisch Weekblad ; 156(1-2):12-15, 2021.
Article in Dutch | Scopus | ID: covidwho-1068437
19.
Pharmaceutisch Weekblad ; 155(37):20-23, 2020.
Article in Dutch | Scopus | ID: covidwho-962125
SELECTION OF CITATIONS
SEARCH DETAIL